Market Cap 24.27M
Revenue (ttm) 0.00
Net Income (ttm) -21.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,953,600
Avg Vol 3,393,164
Day's Range N/A - N/A
Shares Out 49.50M
Stochastic %K 51%
Beta 1.59
Analysts Strong Sell
Price Target $6.67

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology
Sector: Healthcare
Phone: (713) 300-5160
Address:
5300 Memorial Drive, Suite 950, Houston, United States
IVALTE
IVALTE Oct. 25 at 1:00 PM
$MBRX Is not sense to be $0,50 while experts said that can reach $4
0 · Reply
Stormra
Stormra Oct. 24 at 1:58 PM
0 · Reply
Stormra
Stormra Oct. 24 at 1:57 PM
$MBRX https://www.tipranks.com/news/ratings/moleculin-biotechs-promising-drug-pipeline-and-strategic-expansion-justify-buy-rating-ratings $INO $TRNR $AREB
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 23 at 5:20 PM
GIPR about to breakout! The combo is rare – Real assets – Strong tenant quality – Undervalued structure – No dilution is bottomed, coiled, and ready. Chart compression like this always leads to a decision and the upside is wide. $PRFX $SNMP $NAOV $MBRX $ADTX
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 23 at 4:51 PM
If you’re seeking asymmetric upside, check out GIPR. It’s trading at a steep discount to what its asset base suggests, with few eyes on it and potential for a rerate if narrative shifts. This could be the hidden gem in the REIT space. $MBRX $VTEX $RR $EJH
0 · Reply
MessiMagic
MessiMagic Oct. 23 at 2:12 PM
$MBRX this news will attract more investors and also bring more confidence. Let’s see what happens!
0 · Reply
DARKP00L
DARKP00L Oct. 23 at 1:36 PM
$MBRX 09:28 on Oct. 23 2025 Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer #tradeideas
0 · Reply
Stormra
Stormra Oct. 23 at 1:33 PM
$MBRX Yes! Yes! Yes!
0 · Reply
Stormra
Stormra Oct. 23 at 1:13 PM
$MBRX Moleculin Biotech Enters Collaboration With Atlantic Health On An Investigator-Initiated Phase 1B/2 Study To Evaluate Its Drug Candidate Annamycin As A Third-Line Treatment For Advanced Pancreatic Cancer. $AREB $INO $TRNR
0 · Reply
Stormra
Stormra Oct. 23 at 1:10 PM
$MBRX Reuters 24 minutes ago Oct 23 (Reuters) - Moleculin Biotech Inc (MBRX.NaE): * MOLECULIN ANNOUNCES NEW INVESTIGATOR-INITIATED STUDY OF ANNAMYCIN FOR TREATING PANCREATIC CANCER * MOLECULIN BIOTECH INC (MBRX.NaE) - ESTIMATES TRIAL COST AT $1.X MILLION FROM 2026 TO 2030 Source text: Further company coverage:
0 · Reply
Latest News on MBRX
Moleculin Issues New Positive AML Overall Survival Data:

Aug 27, 2025, 8:45 AM EDT - 2 months ago

Moleculin Issues New Positive AML Overall Survival Data:


Moleculin Announces $5.9 Million Public Offering

Jun 20, 2025, 9:20 AM EDT - 4 months ago

Moleculin Announces $5.9 Million Public Offering


Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:20 PM EDT - 5 months ago

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript


Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 10:50 AM EDT - 7 months ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript


Moleculin to Present at the 37th Annual ROTH Conference

Mar 10, 2025, 8:45 AM EDT - 8 months ago

Moleculin to Present at the 37th Annual ROTH Conference


Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 11:17 AM EST - 1 year ago

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript


IVALTE
IVALTE Oct. 25 at 1:00 PM
$MBRX Is not sense to be $0,50 while experts said that can reach $4
0 · Reply
Stormra
Stormra Oct. 24 at 1:58 PM
0 · Reply
Stormra
Stormra Oct. 24 at 1:57 PM
$MBRX https://www.tipranks.com/news/ratings/moleculin-biotechs-promising-drug-pipeline-and-strategic-expansion-justify-buy-rating-ratings $INO $TRNR $AREB
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 23 at 5:20 PM
GIPR about to breakout! The combo is rare – Real assets – Strong tenant quality – Undervalued structure – No dilution is bottomed, coiled, and ready. Chart compression like this always leads to a decision and the upside is wide. $PRFX $SNMP $NAOV $MBRX $ADTX
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 23 at 4:51 PM
If you’re seeking asymmetric upside, check out GIPR. It’s trading at a steep discount to what its asset base suggests, with few eyes on it and potential for a rerate if narrative shifts. This could be the hidden gem in the REIT space. $MBRX $VTEX $RR $EJH
0 · Reply
MessiMagic
MessiMagic Oct. 23 at 2:12 PM
$MBRX this news will attract more investors and also bring more confidence. Let’s see what happens!
0 · Reply
DARKP00L
DARKP00L Oct. 23 at 1:36 PM
$MBRX 09:28 on Oct. 23 2025 Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer #tradeideas
0 · Reply
Stormra
Stormra Oct. 23 at 1:33 PM
$MBRX Yes! Yes! Yes!
0 · Reply
Stormra
Stormra Oct. 23 at 1:13 PM
$MBRX Moleculin Biotech Enters Collaboration With Atlantic Health On An Investigator-Initiated Phase 1B/2 Study To Evaluate Its Drug Candidate Annamycin As A Third-Line Treatment For Advanced Pancreatic Cancer. $AREB $INO $TRNR
0 · Reply
Stormra
Stormra Oct. 23 at 1:10 PM
$MBRX Reuters 24 minutes ago Oct 23 (Reuters) - Moleculin Biotech Inc (MBRX.NaE): * MOLECULIN ANNOUNCES NEW INVESTIGATOR-INITIATED STUDY OF ANNAMYCIN FOR TREATING PANCREATIC CANCER * MOLECULIN BIOTECH INC (MBRX.NaE) - ESTIMATES TRIAL COST AT $1.X MILLION FROM 2026 TO 2030 Source text: Further company coverage:
0 · Reply
Whales22
Whales22 Oct. 23 at 5:59 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $AZTR $GIS $TNON $MBRX Watchlist!
0 · Reply
Waja215
Waja215 Oct. 22 at 8:00 PM
0 · Reply
IVALTE
IVALTE Oct. 22 at 7:42 PM
$MBRX teleleco
0 · Reply
aj_hollins
aj_hollins Oct. 22 at 4:13 PM
$MBRX no public news yet on their site for October - praying we get something by next Friday (10/31).
0 · Reply
jkgyuool
jkgyuool Oct. 22 at 4:11 PM
$MBRX they want their money and they don’t care how much damage they do to the share price. Bastards.
1 · Reply
teedatrader
teedatrader Oct. 22 at 3:22 PM
$MBRX market is looking like TRASH - let's get an atmospheric squeeze to have some fun.
0 · Reply
Zdxss1
Zdxss1 Oct. 22 at 9:38 AM
$MBRX Pumping a million shares into the market. There is no reason to pump a million shares at such a low price at such a sensitive time other than to push the stock down. Who benefits from this?
0 · Reply
stockusfrance
stockusfrance Oct. 22 at 5:55 AM
$MBRX Interested but they are Going to do dilution imo
0 · Reply
Zdxss1
Zdxss1 Oct. 21 at 8:28 PM
$MBRX We have to wait for the 64 million shares offered to be registered on the Nasdaq. It will take two weeks, and we might see a rise in the share price by the end of next week. The Nasdaq serves the big fish, so you should follow it.
2 · Reply
makedatbread88
makedatbread88 Oct. 21 at 5:49 PM
$MBRX this one is dirt dirt cheap here and can be a squeeze candidate bottom looks in on this one
0 · Reply
aj_hollins
aj_hollins Oct. 21 at 1:57 PM
$MBRX patience <3
0 · Reply
Blocktatch
Blocktatch Oct. 20 at 12:20 PM
$MBRX today!!!!!!!
0 · Reply